DK3377500T3 - Oxadiazaspiro-forbindelser til behandling af stofmisbrug og -afhængighed - Google Patents

Oxadiazaspiro-forbindelser til behandling af stofmisbrug og -afhængighed Download PDF

Info

Publication number
DK3377500T3
DK3377500T3 DK16797458.3T DK16797458T DK3377500T3 DK 3377500 T3 DK3377500 T3 DK 3377500T3 DK 16797458 T DK16797458 T DK 16797458T DK 3377500 T3 DK3377500 T3 DK 3377500T3
Authority
DK
Denmark
Prior art keywords
dependence
treatment
drug abuse
oxadiazaspiro
compounds
Prior art date
Application number
DK16797458.3T
Other languages
English (en)
Inventor
Marina Virgili-Bernado
Carmen Almansa-Rosales
Carlos Alegret-Molina
Original Assignee
Esteve Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Pharmaceuticals Sa filed Critical Esteve Pharmaceuticals Sa
Application granted granted Critical
Publication of DK3377500T3 publication Critical patent/DK3377500T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
DK16797458.3T 2015-11-16 2016-11-15 Oxadiazaspiro-forbindelser til behandling af stofmisbrug og -afhængighed DK3377500T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15382566 2015-11-16
PCT/EP2016/001907 WO2017084752A1 (en) 2015-11-16 2016-11-15 Oxadiazaspiro compounds for the treatment of drug abuse and addiction

Publications (1)

Publication Number Publication Date
DK3377500T3 true DK3377500T3 (da) 2022-11-21

Family

ID=54707728

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16797458.3T DK3377500T3 (da) 2015-11-16 2016-11-15 Oxadiazaspiro-forbindelser til behandling af stofmisbrug og -afhængighed

Country Status (29)

Country Link
US (2) US10927128B2 (da)
EP (1) EP3377500B1 (da)
JP (1) JP6884974B2 (da)
KR (2) KR20180080327A (da)
CN (1) CN108349999A (da)
AR (1) AR106697A1 (da)
AU (1) AU2016356488B2 (da)
CO (1) CO2018004665A2 (da)
DK (1) DK3377500T3 (da)
ES (1) ES2932000T3 (da)
HR (1) HRP20221343T1 (da)
HU (1) HUE060275T2 (da)
IL (1) IL259035B (da)
LT (1) LT3377500T (da)
MA (1) MA43250B1 (da)
MX (1) MX384637B (da)
MY (1) MY193423A (da)
PH (1) PH12018500814A1 (da)
PL (1) PL3377500T3 (da)
PT (1) PT3377500T (da)
RS (1) RS63734B1 (da)
SG (1) SG11201803153RA (da)
SI (1) SI3377500T1 (da)
SM (1) SMT202200460T1 (da)
TN (1) TN2018000122A1 (da)
TW (1) TWI756196B (da)
UA (1) UA123775C2 (da)
WO (1) WO2017084752A1 (da)
ZA (1) ZA201802845B (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA123775C2 (uk) 2015-11-16 2021-06-02 Естев Фармас'Ютікалз, С.А. Оксадіазаспіросполуки для лікування зловживання наркотичними засобами та залежності від них
WO2020157026A1 (en) * 2019-01-28 2020-08-06 Esteve Pharmaceuticals, S.A. Hydroxylated derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
WO2023041713A1 (en) 2021-09-20 2023-03-23 Esteve Pharmaceuticals, S.A. Oxadiazaspiro compounds for use in the treatment of motoneuron degeneration or in neuroprotection
WO2024105225A1 (en) 2022-11-18 2024-05-23 Universitat De Barcelona Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4244961A (en) * 1978-10-26 1981-01-13 Syntex (U.S.A.) Inc. 1-Oxa-3,8-diazaspiro[4.5]decan-2-ones antihypertensive agents
US4332804A (en) 1981-03-23 1982-06-01 Syntex (U.S.A.) Inc. 9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones
US4353900A (en) 1981-10-19 1982-10-12 Syntex (U.S.A.) Inc. 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones
US4353901A (en) * 1981-10-19 1982-10-12 Syntex (U.S.A.) Inc. 9-(1,4-Benzodioxan-2-ylalkyl and hydroxyalkyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-ones
US6114541A (en) 1997-03-10 2000-09-05 Hoffmann-La Roche Inc. Method for the preparation of α-Bromo-Lactam derivatives
KR100863854B1 (ko) * 2004-02-10 2008-10-15 에프. 호프만-라 로슈 아게 케모카인 ｃｃｒ5 수용체 조절제
CA2557354C (en) 2004-03-03 2013-05-07 Vital Health Sciences Pty Ltd. Alkaloid formulations
JP5135795B2 (ja) * 2004-08-27 2013-02-06 小野薬品工業株式会社 塩基性基を含有する化合物およびその用途
EP1634873A1 (en) 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
CN101228127B (zh) 2005-05-30 2012-05-16 Msdk.K.公司 哌啶衍生物
CN101203567A (zh) * 2005-06-07 2008-06-18 西巴特殊化学品控股有限公司 抗刮擦聚烯烃
DE102005030051A1 (de) 2005-06-27 2006-12-28 Grünenthal GmbH Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
KR101347102B1 (ko) 2005-10-19 2014-01-03 그뤼넨탈 게엠베하 신규한 바닐로이드 수용체 리간드 및 약제를 제조하기 위한이의 용도
EP1961744B1 (en) 2005-11-18 2013-04-17 Ono Pharmaceutical Co., Ltd. Basic group-containing compound and use thereof
EP1829869A1 (en) 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. 4,5,6,7-Tetrahydrobenzo[b]thiophene derivatives and their use as sigma receptor ligands
EP1847542A1 (en) 2006-04-21 2007-10-24 Laboratorios del Dr. Esteve S.A. Spiro[benzopyran] or spiro[benzofuran] derivatives which inhibit the sigma receptor
MX2009009355A (es) 2007-03-01 2009-09-11 Mitsubishi Tanabe Pharma Corp Compuesto de bencimidazol y uso farmaceutico del mismo.
EP1982714A1 (en) 2007-04-16 2008-10-22 Laboratorios del Dr. Esteve S.A. Pyrano-pyrazole-amines
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
US20110190280A1 (en) 2007-08-29 2011-08-04 George Adjabeng Thiazole And Oxazole Kinase Inhibitors
EP2070933A1 (en) 2007-12-07 2009-06-17 Laboratorios del Dr. Esteve S.A. Tricyclic triazolic compounds
KR101273200B1 (ko) 2008-02-06 2013-06-17 펄마젠 쎄라퓨틱스 (시너지) 리미티드 화합물
EP2108643A1 (en) * 2008-04-10 2009-10-14 Laboratorios Del. Dr. Esteve, S.A. 4-methyl-4, 5-dihydro-1H-pyrazole-3-carboxamide useful as a cannabinoid CB1 neutral antagonist
GB201016912D0 (en) * 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
US8828996B2 (en) 2011-03-14 2014-09-09 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
GB201107985D0 (en) 2011-05-13 2011-06-29 Astrazeneca Ab Process
WO2013052716A1 (en) * 2011-10-07 2013-04-11 Glaxosmithkline Llc Fatty acid synthase inhibitors
JPWO2013115294A1 (ja) 2012-01-31 2015-05-11 東レ株式会社 ジアザスピロウレア誘導体及びその医薬用途
WO2015017305A1 (en) 2013-07-31 2015-02-05 Merck Sharp & Dohme Corp Inhibitors of the renal outer medullary potassium channel
TWI685497B (zh) * 2014-06-02 2020-02-21 西班牙商伊史帝夫製藥公司 具有多重模式抗疼痛活性的１-氧雜-４,９-二氮雜螺十一烷化合物之烷基衍生物
TW201615643A (zh) 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 具有多重模式抗疼痛活性之１－氧雜－４，９－二氮雜螺十一烷化合物之烷基與芳基衍生物
TW201615642A (zh) 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 具有多重模式抗疼痛活性的１－氧雜－４，９－二氮雜螺十一烷化合物之醯胺衍生物
US10513518B2 (en) * 2015-01-29 2019-12-24 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
UA123775C2 (uk) 2015-11-16 2021-06-02 Естев Фармас'Ютікалз, С.А. Оксадіазаспіросполуки для лікування зловживання наркотичними засобами та залежності від них

Also Published As

Publication number Publication date
KR20180080327A (ko) 2018-07-11
CA3002286A1 (en) 2017-05-26
HUE060275T2 (hu) 2023-02-28
KR20250069710A (ko) 2025-05-19
SMT202200460T1 (it) 2023-01-13
MY193423A (en) 2022-10-12
EP3377500A1 (en) 2018-09-26
PH12018500814A1 (en) 2018-10-29
AU2016356488B2 (en) 2020-10-22
WO2017084752A1 (en) 2017-05-26
SI3377500T1 (sl) 2023-02-28
ES2932000T3 (es) 2023-01-09
JP6884974B2 (ja) 2021-06-09
EP3377500B1 (en) 2022-10-19
MA43250A (fr) 2021-04-14
IL259035A (en) 2018-06-28
US20210115062A1 (en) 2021-04-22
PL3377500T3 (pl) 2023-01-23
US11649248B2 (en) 2023-05-16
CN108349999A (zh) 2018-07-31
SG11201803153RA (en) 2018-06-28
US10927128B2 (en) 2021-02-23
AR106697A1 (es) 2018-02-07
RU2018120748A (ru) 2019-12-05
TW201731854A (zh) 2017-09-16
UA123775C2 (uk) 2021-06-02
PT3377500T (pt) 2022-11-25
TN2018000122A1 (en) 2019-10-04
BR112018009279A8 (pt) 2019-02-26
JP2018533598A (ja) 2018-11-15
AU2016356488A1 (en) 2018-05-10
MX384637B (es) 2025-03-14
IL259035B (en) 2021-06-30
LT3377500T (lt) 2022-12-12
RU2018120748A3 (da) 2020-02-07
HRP20221343T1 (hr) 2022-12-23
TWI756196B (zh) 2022-03-01
RS63734B1 (sr) 2022-12-30
MA43250B1 (fr) 2022-12-30
US20180327422A1 (en) 2018-11-15
MX2018005439A (es) 2018-11-09
ZA201802845B (en) 2021-10-27
CO2018004665A2 (es) 2018-07-19
BR112018009279A2 (pt) 2018-11-06

Similar Documents

Publication Publication Date Title
IL258931A (en) Therapeutic compounds and methods
DK3501542T3 (da) Esketamin til behandling af depression
DK3349758T3 (da) Fremgangsmåder til behandling af arenaviridae-virusinfektioner
DK3521282T3 (da) Quinazolinderivater anvendt til behandling af hiv
DK3173092T3 (da) Rna-holdig sammensætning til behandling af tumorsygdomme
DK3288581T3 (da) Fremgangsmåde til behandling af cancer
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3331915T3 (da) Immun-checkpoint-inhibitorer til anvendelse til behandling af blodbårne cancere
DK3882250T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3244948T3 (da) Bestemmelse af medikamentdosis
DK3119397T3 (da) Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
DK3307262T3 (da) Forbindelser til anvendelse ved behandling af neuromuskulære lidelser
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3328864T3 (da) Terapeutiske forbindelser og sammensætninger til behandling af sociale forstyrrelser og stofmisbrugsforstyrrelser
DK3390390T3 (da) Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
DK3503890T3 (da) Anvendelse af pridopidin til behandling af dystonier
DK3099298T3 (da) Kombinationsterapier med zidovudin til behandling af mikrobielle infektioner
DK3524255T3 (da) Sammensætning til behandling af acne
DK3331879T3 (da) Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne
DK3324824T3 (da) Fremgangsmåde til behandling af binokulare dysfunktioner
DK3710000T3 (da) Tradipitant til anvendelse til behandling af gastroparese